Bipartisan House bill seeks new $30B ‘BioBonds’ loan program to reinvigorate clinical trials
As thousands of clinical trials were suspended or halted due to the Covid-19 pandemic over the last year, House members on both sides of the aisle are trying to find new ways to jumpstart the clinical trial ecosystem.
For those with an IND in hand, and pursuing a drug targeting an unmet need, Reps. Bobby Rush (D-IL) and Brian Fitzpatrick (R-PA) on Friday introduced a new bill that would provide loans to continue such research if other funding sources run dry.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.